{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:15:00Z","timestamp":1789442100972,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973256\/H3008"],"award-info":[{"award-number":["81973256\/H3008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.apsb.2020.06.006","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T21:59:25Z","timestamp":1592517565000},"page":"2384-2403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption"],"prefix":"10.1016","volume":"10","author":[{"given":"Yanjuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanghong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.06.006_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2018.01.003","article-title":"Breast cancer bone metastases: pathogenesis and therapeutic targets","volume":"96","author":"Brook","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2020.06.006_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.apsb.2020.06.006_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.apsb.2020.06.006_bib4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13058-014-0484-9","article-title":"Role of bone-anabolic agents in the treatment of breast cancer bone metastases","volume":"16","author":"Suvannasankha","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib5","first-page":"3557","article-title":"Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer","volume":"24","author":"Cleeland","year":"2016","journal-title":"Support Care Canc"},{"key":"10.1016\/j.apsb.2020.06.006_bib6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00109-015-1329-4","article-title":"Bone metastasis and the metastatic niche","volume":"93","author":"Ren","year":"2015","journal-title":"J Mol Med"},{"key":"10.1016\/j.apsb.2020.06.006_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrclinonc.2011.198","article-title":"Bone cancer in 2011: prevention and treatment of bone metastases","volume":"9","author":"Coleman","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2020.06.006_bib8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1148\/radiology.149.3.6316414","article-title":"New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate","volume":"149","author":"Subramanian","year":"1983","journal-title":"Radiology"},{"key":"10.1016\/j.apsb.2020.06.006_bib9","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.06.006_bib10","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2020.06.006_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.06.006_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/222385a0","article-title":"Platinum compounds: a new class of potent antitumour agents","volume":"222","author":"Rosenberg","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.06.006_bib14","doi-asserted-by":"crossref","first-page":"8726","DOI":"10.1016\/j.biomaterials.2013.07.092","article-title":"Controlled release of cisplatin from pH-thermal dual responsive nanogels","volume":"34","author":"Peng","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.06.006_bib15","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2020.06.006_bib16","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1021\/acs.chemrev.5b00125","article-title":"Nanomedicine applications of hybrid nanomaterials built from metal\u2013ligand coordination bonds: nanoscale metal\u2013organic frameworks and nanoscale coordination polymers","volume":"115","author":"He","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2020.06.006_bib17","doi-asserted-by":"crossref","first-page":"14652","DOI":"10.1021\/ja9071282","article-title":"Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum (IV) warheads","volume":"131","author":"Dhar","year":"2009","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2020.06.006_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cej.2018.09.076","article-title":"Glutathione and H2O2 consumption promoted photodynamic and chemotherapy based on biodegradable MnO2\u2013Pt@ Au25 nanosheets","volume":"356","author":"Bi","year":"2019","journal-title":"Chem Eng J"},{"key":"10.1016\/j.apsb.2020.06.006_bib19","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1016\/j.biomaterials.2011.08.022","article-title":"Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery","volume":"32","author":"Yang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.06.006_bib20","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1039\/C7TB02513K","article-title":"Targeted delivery of a guanidine-pendant Pt (IV)-backboned poly-prodrug by an anisamide-functionalized polypeptide","volume":"5","author":"Li","year":"2017","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2020.06.006_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.biomaterials.2017.11.014","article-title":"Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in\u00a0vitro and in\u00a0vivo","volume":"155","author":"Yu","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.06.006_bib22","doi-asserted-by":"crossref","first-page":"11584","DOI":"10.1021\/ja803383k","article-title":"Nanoscale coordination polymers for platinum-based anticancer drug delivery","volume":"130","author":"Rieter","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2020.06.006_bib23","doi-asserted-by":"crossref","first-page":"1605926","DOI":"10.1002\/adfm.201605926","article-title":"Nanoscale-coordination-polymer-shelled manganese dioxide composite nanoparticles: a multistage redox\/pH\/H2O2-responsive cancer theranostic nanoplatform","volume":"27","author":"Liu","year":"2017","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2020.06.006_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2017.08.024","article-title":"Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer","volume":"264","author":"He","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.06.006_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J Angiogene Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2020.06.006_bib27","first-page":"2747s","article-title":"Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the \u201cbinding site barrier\u201d","volume":"52","author":"Weinstein","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib28","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1039\/C7NR02662E","article-title":"Coordination self-assembly of platinum\u2013bisphosphonate polymer\u2013metal complex nanoparticles for cisplatin delivery and effective cancer therapy","volume":"9","author":"Huang","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2020.06.006_bib29","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1039\/C7NR05402E","article-title":"Phthalocyanine-based coordination polymer nanoparticles for enhanced photodynamic therapy","volume":"9","author":"Huang","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2020.06.006_bib30","doi-asserted-by":"crossref","first-page":"122369","DOI":"10.1016\/j.cej.2019.122369","article-title":"Three birds with one stone: a ferric pyrophosphate based nanoagent for synergetic NIR-triggered photo\/chemodynamic therapy with glutathione depletion","volume":"380","author":"Huang","year":"2020","journal-title":"Chem Eng J"},{"key":"10.1016\/j.apsb.2020.06.006_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2019.12.043","article-title":"A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways","volume":"319","author":"Huang","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.06.006_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.biomaterials.2015.12.018","article-title":"Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone antiresorptive agent into an anticancer therapeutic","volume":"82","author":"Au","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.06.006_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijpharm.2016.11.051","article-title":"Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis","volume":"516","author":"Chu","year":"2017","journal-title":"Int J Pharm (Amst)"},{"key":"10.1016\/j.apsb.2020.06.006_bib34","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.apsb.2019.03.006","article-title":"Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer","volume":"9","author":"Mei","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.06.006_bib36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bbrc.2010.09.053","article-title":"Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production","volume":"401","author":"He","year":"2010","journal-title":"Biochem Bioph Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00774-008-0018-6","article-title":"The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions","volume":"27","author":"Vincent","year":"2009","journal-title":"J Bone Miner Metabol"},{"key":"10.1016\/j.apsb.2020.06.006_bib38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3892\/ijmm.2016.2477","article-title":"The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells","volume":"37","author":"Kim","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.apsb.2020.06.006_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2014.10.012","article-title":"RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer","volume":"196","author":"Wang","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.06.006_bib40","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.apsb.2019.01.015","article-title":"Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-\u03baB\/MAPK signaling and protecting chondrocytes","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.06.006_bib41","unstructured":"Glausch A, Loeffler R, Sigg J, inventors. Pharmaceutical products comprising bisphosphonates. United States Patent US7932241B2. 2003 September 18."},{"key":"10.1016\/j.apsb.2020.06.006_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0014-4827(88)90191-7","article-title":"Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts","volume":"175","author":"Silver","year":"1988","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib43","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.2215\/CJN.04151206","article-title":"Normal bone anatomy and physiology","volume":"3","author":"Clarke","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2020.06.006_bib44","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"P Natl A Sci India B"},{"key":"10.1016\/j.apsb.2020.06.006_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.apsb.2020.06.006_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","article-title":"Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in\u00a0vivo and in MCF-7 cells in\u00a0vitro","volume":"157","author":"R\u00e4ikk\u00f6nen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.06.006_bib47","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3892\/ijo.2013.1809","article-title":"Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Corrigendum in\/10.3892\/ijo. 2016.3613","volume":"42","author":"Ibrahim","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2020.06.006_bib48","doi-asserted-by":"crossref","first-page":"39458","DOI":"10.1074\/jbc.M006626200","article-title":"Regulation of apoptosis and cell cycle progression by MCL1 differential role of proliferating cell nuclear antigen","volume":"275","author":"Fujise","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2020.06.006_bib49","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC clinical trials group IND. 163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.06.006_bib50","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.06.006_bib51","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2020.06.006_bib52","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1021\/acsnano.8b02881","article-title":"Quantitative assessment of nanoparticle biodistribution by fluorescence imaging, revisited","volume":"12","author":"Meng","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2020.06.006_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2017.06.006","article-title":"Comprehensive study of the drug delivery properties of poly (l-lactide)-poly (ethylene glycol) nanoparticles in rats and tumor-bearing mice","volume":"261","author":"Shalgunov","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.06.006_bib54","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2020.06.006_bib55","first-page":"380","article-title":"Skeletal metastasis: treatments, mouse models, and the Wnt signaling","volume":"32","author":"Valkenburg","year":"2013","journal-title":"Chin J Canc"},{"key":"10.1016\/j.apsb.2020.06.006_bib56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2020.06.006_bib57","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1021\/acsnano.9b00097","article-title":"Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis","volume":"13","author":"Sun","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2020.06.006_bib58","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1166\/jbn.2018.2646","article-title":"Self-assembled hydroxyapatite-graphene scaffold for photothermal cancer therapy and bone regeneration","volume":"14","author":"Li","year":"2018","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.apsb.2020.06.006_bib59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.apsb.2019.11.004","article-title":"Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1\u03b2 expression","volume":"10","author":"Son","year":"2020","journal-title":"Acta Pharm Sin B"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520306158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520306158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:44:52Z","timestamp":1761929092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383520306158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2211383520306158"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.06.006","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}